Mingquan Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mingquan Li has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Lina Feng
Department of Neurology, the Second Affiliated Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, China
14 shared publications Cong Li
Changchun University of Traditional Chinese Medicine, Changchun, China
5 shared publicationsBaicheng Ning
College of Integrated Chinese and Western Medicine, Changchun University of Chinese Medicine
4 shared publications- Huiying Yan
Department of Neurology, the Third Affiliated Clinical Hospital of the Changchun University of Chinese Medicine, Changchun, Jilin Province, People’s Republic of China
3 shared publications - Qile Song
Shandong Key Laboratory of TCM Multi-Target Intervention and Disease Control, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, 271000, China
3 shared publications - Xiaoting Zhu
The Third Clinical Hospital of Changchun University of Traditional Chinese Medicine, Changchun, China
3 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (11) , 1217
Progress in the Application of Chitosan Derivatives for Diabetic Wound Healing: From Material Design to Microenvironment Modulation
Delayed wound healing in diabetes mellitus represents a formidable clinical challenge, characterized by core pathological hallmarks including persistent inflammation, impaired angiogenesis, excessive oxidative stress, and heightened infectivity. Chitosan, a natural cationic polysaccharide, exhibits inherent advantages such as biocompatibility, hemostatic activity, and antibacterial properties; however, its poor solubility at neutral pH and insufficient mechanical performance have constrained its clinical utility. Chemical derivatization—encompassing carboxymethylation, quaternization, thiolation, phosphorylation, and arginine grafting—modulates chitosan’s solubility, charge, and functional groups in a derivative-specific manner, so that individual derivatives acquire distinct antibacterial, antioxidant, immunomodulatory, pro-angiogenic, or ECM-remodeling activities rather than a uniform set of functions. Derivative-based smart hydrogels, such as glucose/pH dual-responsive, immunomodulatory, pro-angiogenic, and antioxidant/antibacterial systems, are designed to target selected pathological features of the diabetic wound microenvironment rather than all features simultaneously. By exerting a cascading effect of “ glucose regulation–antibacterial action–repair promotion,” these hydrogels effectively disrupt the stagnation of wound healing. This review systematically summarizes the types of chitosan derivatives, their modification strategies, and recent advances in their application for diabetic wound healing. Additionally, it analyzes the challenges hindering clinical translation and outlines future research directions.
- 13 November 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (11) , 1217
Open AccessProgress in the Application of Chitosan Derivatives for Diabetic Wound Healing: From Material Design to Microenvironment Modulation
Delayed wound healing in diabetes mellitus represents a formidable clinical challenge, characterized by core pathological hallmarks including persistent inflammation, impaired angiogenesis, excessive oxidative stress, and heightened infectivity. Chitosan, a natural cationic polysaccharide, exhibits inherent advantages such as biocompatibility, hemostatic activity, and antibacterial properties; however, its poor solubility at neutral pH and insufficient mechanical performance have constrained its clinical utility. Chemical derivatization—encompassing carboxymethylation, quaternization, thiolation, phosphorylation, and arginine grafting—modulates chitosan’s solubility, charge, and functional groups in a derivative-specific manner, so that individual derivatives acquire distinct antibacterial, antioxidant, immunomodulatory, pro-angiogenic, or ECM-remodeling activities rather than a uniform set of functions. Derivative-based smart hydrogels, such as glucose/pH dual-responsive, immunomodulatory, pro-angiogenic, and antioxidant/antibacterial systems, are designed to target selected pathological features of the diabetic wound microenvironment rather than all features simultaneously. By exerting a cascading effect of “ glucose regulation–antibacterial action–repair promotion,” these hydrogels effectively disrupt the stagnation of wound healing. This review systematically summarizes the types of chitosan derivatives, their modification strategies, and recent advances in their application for diabetic wound healing. Additionally, it analyzes the challenges hindering clinical translation and outlines future research directions.
- Open Access
- 14 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1976119
Luteolin for Alzheimer's disease and related cognitive impairment: a systematic review and meta-analysis of efficacy and molecular mechanisms
Background: The multifactorial pathogenesis of Alzheimer's disease (AD) renders conventional single-target therapies largely ineffective. Luteolin, a natural flavonoid, has demonstrated promising pleiotropic neuroprotective potential. This study aims to systematically evaluate the preclinical efficacy and multi-target mechanisms of luteolin in rodent models of AD and associated cognitive impairment. Methods: Eight major electronic databases were systematically searched from January 1, 2000 to June 1, 2026. In vivo preclinical studies evaluating luteolin monotherapy in AD-specific and general cognitive impairment rodent models were included. Methodological quality was assessed using the SYRCLE risk of bias tool. Standardized mean differences and 95% confidence intervals were calculated using a random-effects model. Results: Fifteen eligible studies were included. Meta-analysis revealed that luteolin significantly ameliorated cognitive and memory impairments in both AD-specific and non-AD cognitive impairment models. Mechanistically, luteolin significantly restored redox homeostasis and suppressed neuroinflammatory cascades at both transcriptional and translational levels. Subgroup analyses indicated that oral administration and prolonged interventions were associated with significant efficacy; however, these observations are heavily influenced by study-level confounding and cannot conclusively establish pharmacokinetic superiority. Furthermore, the certainty of evidence is limited by predominantly unclear risks of bias, substantial statistical heterogeneity, and potential publication bias. Conclusion: Current preclinical evidence suggests that luteolin is a promising multi-target neuroprotective candidate for AD and related cognitive impairments, highlighted by its anti-inflammatory and antioxidant properties. However, given the substantial methodological limitations and extremely large pooled effect sizes, these findings must be interpreted with caution. Future research must prioritize rigorous preclinical designs, advanced brain-targeted delivery systems, and GLP-compliant toxicological profiling before clinical translation.
- 14 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1976119
Open AccessLuteolin for Alzheimer's disease and related cognitive impairment: a systematic review and meta-analysis of efficacy and molecular mechanisms
Background: The multifactorial pathogenesis of Alzheimer's disease (AD) renders conventional single-target therapies largely ineffective. Luteolin, a natural flavonoid, has demonstrated promising pleiotropic neuroprotective potential. This study aims to systematically evaluate the preclinical efficacy and multi-target mechanisms of luteolin in rodent models of AD and associated cognitive impairment. Methods: Eight major electronic databases were systematically searched from January 1, 2000 to June 1, 2026. In vivo preclinical studies evaluating luteolin monotherapy in AD-specific and general cognitive impairment rodent models were included. Methodological quality was assessed using the SYRCLE risk of bias tool. Standardized mean differences and 95% confidence intervals were calculated using a random-effects model. Results: Fifteen eligible studies were included. Meta-analysis revealed that luteolin significantly ameliorated cognitive and memory impairments in both AD-specific and non-AD cognitive impairment models. Mechanistically, luteolin significantly restored redox homeostasis and suppressed neuroinflammatory cascades at both transcriptional and translational levels. Subgroup analyses indicated that oral administration and prolonged interventions were associated with significant efficacy; however, these observations are heavily influenced by study-level confounding and cannot conclusively establish pharmacokinetic superiority. Furthermore, the certainty of evidence is limited by predominantly unclear risks of bias, substantial statistical heterogeneity, and potential publication bias. Conclusion: Current preclinical evidence suggests that luteolin is a promising multi-target neuroprotective candidate for AD and related cognitive impairments, highlighted by its anti-inflammatory and antioxidant properties. However, given the substantial methodological limitations and extremely large pooled effect sizes, these findings must be interpreted with caution. Future research must prioritize rigorous preclinical designs, advanced brain-targeted delivery systems, and GLP-compliant toxicological profiling before clinical translation.
- Open Access
- 10 September 2026
- Published by Wiley in Aging Cell
- Vol. 25 (9) , e70699
Novel Therapeutic Insights Into Alzheimer's Disease: Glymphatic System and Meningeal Lymphatic Vessels
With the acceleration of global aging, the relationship between Alzheimer's disease (AD) and the glymphatic system (GS) has become a research hotspot in the field of neuroscience in recent years. Traditionally, the central nervous system was thought to lack a lymphatic system; however, research over the past decade has overturned this view. Studies have revealed the existence of GS and meningeal lymphatic vessels (mLVs) in the brain, which clear metabolic waste (such as amyloid‐β and tau proteins) through the exchange of cerebrospinal fluid (CSF) and interstitial fluid (ISF). Dysfunction of the GS can lead to abnormal deposition of pathological proteins, which may trigger or exacerbate AD. Currently, the association between the GS and AD treatment mainly focuses on drug development (such as small molecules that promote glymphatic circulation), physical therapies (such as 40 Hz photoacoustic therapy), and surgical interventions (primarily deep cervical lymphatic‐vein anastomosis and cranial bone maneuver), all of which are under exploration. With the precision of diagnostic technologies and the targeting of therapeutic methods, future intervention strategies surrounding GS may become a significant breakthrough in overcoming the treatment impasse of AD, bringing new hope to tens of millions of AD patients worldwide.
- 10 September 2026
- Published by Wiley in Aging Cell
- Vol. 25 (9) , e70699
Open AccessNovel Therapeutic Insights Into Alzheimer's Disease: Glymphatic System and Meningeal Lymphatic Vessels
With the acceleration of global aging, the relationship between Alzheimer's disease (AD) and the glymphatic system (GS) has become a research hotspot in the field of neuroscience in recent years. Traditionally, the central nervous system was thought to lack a lymphatic system; however, research over the past decade has overturned this view. Studies have revealed the existence of GS and meningeal lymphatic vessels (mLVs) in the brain, which clear metabolic waste (such as amyloid‐β and tau proteins) through the exchange of cerebrospinal fluid (CSF) and interstitial fluid (ISF). Dysfunction of the GS can lead to abnormal deposition of pathological proteins, which may trigger or exacerbate AD. Currently, the association between the GS and AD treatment mainly focuses on drug development (such as small molecules that promote glymphatic circulation), physical therapies (such as 40 Hz photoacoustic therapy), and surgical interventions (primarily deep cervical lymphatic‐vein anastomosis and cranial bone maneuver), all of which are under exploration. With the precision of diagnostic technologies and the targeting of therapeutic methods, future intervention strategies surrounding GS may become a significant breakthrough in overcoming the treatment impasse of AD, bringing new hope to tens of millions of AD patients worldwide.
- Open Access
- 24 June 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1815489
Comparison of the effects of different traditional Chinese exercises on improving the motor function of stroke survivors: a network meta-analysis and systematic review
Introduction: Stroke survivors frequently present with varying degrees of sensory, cognitive, language, and motor impairments. Traditional Chinese exercises have been widely used as adjunctive rehabilitation therapies because they combine low-to-moderate intensity physical training, balance practice, proprioceptive stimulation, motor relearning, respiratory regulation, and cognitive engagement. However, intervention protocols and outcome measures vary substantially across trials, and direct head-to-head comparisons among Tai Chi, Baduanjin, Wuqinxi, Yijinjing, and standard of care remain scarce. This network meta-analysis therefore compared the relative effectiveness of different traditional Chinese exercise modalities for improving post-stroke motor outcomes. Methods: We systematically searched Embase, Web of Science, Cochrane Library, PubMed, CNKI, VIP, and Wanfang Data from database inception to January 2026 for RCTs evaluating traditional Chinese exercises for post-stroke motor dysfunction. Eligible participants were adults with clinically diagnosed ischemic or hemorrhagic stroke in the acute, subacute, or chronic stage. The primary outcomes were upper- and lower-extremity motor function assessed using the FMA-UE and FMA-LE. Secondary outcomes were balance function assessed using the BBS and activities of daily living assessed using the BI. Risk of bias was assessed using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2). A Bayesian network meta-analysis was performed, and intervention rankings were estimated using the SUCRA. Results: Fifty RCTs involving 3,718 participants were included. Compared with standard of care, Tai Chi and Wuqinxi showed statistically significant improvements in FMA-UE scores, whereas Baduanjin, Tai Chi, and Wuqinxi improved FMA-LE scores. All four exercise modalities were associated with significant improvements in BBS and BI scores. Ranking results suggested that Tai Chi had the highest probability of improving FMA-UE, Wuqinxi ranked highest for FMA-LE, Yijinjing ranked highest for BBS, and Baduanjin ranked highest for BI. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261323853 , CRD420261323853.
- 24 June 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1815489
Open AccessComparison of the effects of different traditional Chinese exercises on improving the motor function of stroke survivors: a network meta-analysis and systematic review
Introduction: Stroke survivors frequently present with varying degrees of sensory, cognitive, language, and motor impairments. Traditional Chinese exercises have been widely used as adjunctive rehabilitation therapies because they combine low-to-moderate intensity physical training, balance practice, proprioceptive stimulation, motor relearning, respiratory regulation, and cognitive engagement. However, intervention protocols and outcome measures vary substantially across trials, and direct head-to-head comparisons among Tai Chi, Baduanjin, Wuqinxi, Yijinjing, and standard of care remain scarce. This network meta-analysis therefore compared the relative effectiveness of different traditional Chinese exercise modalities for improving post-stroke motor outcomes. Methods: We systematically searched Embase, Web of Science, Cochrane Library, PubMed, CNKI, VIP, and Wanfang Data from database inception to January 2026 for RCTs evaluating traditional Chinese exercises for post-stroke motor dysfunction. Eligible participants were adults with clinically diagnosed ischemic or hemorrhagic stroke in the acute, subacute, or chronic stage. The primary outcomes were upper- and lower-extremity motor function assessed using the FMA-UE and FMA-LE. Secondary outcomes were balance function assessed using the BBS and activities of daily living assessed using the BI. Risk of bias was assessed using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2). A Bayesian network meta-analysis was performed, and intervention rankings were estimated using the SUCRA. Results: Fifty RCTs involving 3,718 participants were included. Compared with standard of care, Tai Chi and Wuqinxi showed statistically significant improvements in FMA-UE scores, whereas Baduanjin, Tai Chi, and Wuqinxi improved FMA-LE scores. All four exercise modalities were associated with significant improvements in BBS and BI scores. Ranking results suggested that Tai Chi had the highest probability of improving FMA-UE, Wuqinxi ranked highest for FMA-LE, Yijinjing ranked highest for BBS, and Baduanjin ranked highest for BI. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261323853 , CRD420261323853.
- Open Access
- 27 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (9) , e47842
Causal relationship between obesity and diabetic neuropathy: A 2-sample Mendelian randomization study
A growing body of evidence suggests a potential correlation between obesity and diabetic neuropathy (DN), but the causal nature of this relationship remains uncertain. We conducted a Mendelian randomization (MR) analysis to investigate the causal relationship between obesity and DN. Independent single nucleotide polymorphisms strongly associated with DN were identified from genome-wide association studies. Summary statistics for body mass index (BMI), waist circumference (WC), hip circumference (HC), and waist-to-hip ratio (WHR) were also obtained from genome-wide association studies datasets. The causal effects were estimated using inverse-variance weighted analysis, MR-Egger regression, and weighted median estimation. Sensitivity analyzes were performed to assess the robustness of the findings. Inverse-variance weighted analysis revealed significant negative associations of BMI ( P = .0006, OR = 0.809, 95% CI: 0.716–0.913), WC ( P = .008, OR = 0.792, 95% CI: 0.665–0.943), and HC ( P = .032, OR = 0.871, 95% CI: 0.768–0.988) with DN risk. No significant association was observed for WHR ( P = .425, OR = 0.954, 95% CI: 0.849–1.071). After Bonferroni correction (α = 0.0125), there was a statistically significant relationship between BMI and DN ( P ≤ .0125), indicating a causal relationship. However, the causal relationships between WC, HC, WHR, and DN were not statistically significant, with P -values all > .0125. However, the OR value of MR analysis is close to 1, indicating that BMI may have a slight protective effect on the risk of DN.
- 27 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (9) , e47842
Open AccessCausal relationship between obesity and diabetic neuropathy: A 2-sample Mendelian randomization study
A growing body of evidence suggests a potential correlation between obesity and diabetic neuropathy (DN), but the causal nature of this relationship remains uncertain. We conducted a Mendelian randomization (MR) analysis to investigate the causal relationship between obesity and DN. Independent single nucleotide polymorphisms strongly associated with DN were identified from genome-wide association studies. Summary statistics for body mass index (BMI), waist circumference (WC), hip circumference (HC), and waist-to-hip ratio (WHR) were also obtained from genome-wide association studies datasets. The causal effects were estimated using inverse-variance weighted analysis, MR-Egger regression, and weighted median estimation. Sensitivity analyzes were performed to assess the robustness of the findings. Inverse-variance weighted analysis revealed significant negative associations of BMI ( P = .0006, OR = 0.809, 95% CI: 0.716–0.913), WC ( P = .008, OR = 0.792, 95% CI: 0.665–0.943), and HC ( P = .032, OR = 0.871, 95% CI: 0.768–0.988) with DN risk. No significant association was observed for WHR ( P = .425, OR = 0.954, 95% CI: 0.849–1.071). After Bonferroni correction (α = 0.0125), there was a statistically significant relationship between BMI and DN ( P ≤ .0125), indicating a causal relationship. However, the causal relationships between WC, HC, WHR, and DN were not statistically significant, with P -values all > .0125. However, the OR value of MR analysis is close to 1, indicating that BMI may have a slight protective effect on the risk of DN.
- Open Access
- 14 November 2025
- Published by Association for Computing Machinery (ACM)
- p. 11-18
Analysis of evolutionary trends and hotspots of domestic research on cognitive dysfunction in diabetes mellitus based on clustering algorithm
- 14 November 2025
- Published by Association for Computing Machinery (ACM)
- p. 11-18
Open AccessAnalysis of evolutionary trends and hotspots of domestic research on cognitive dysfunction in diabetes mellitus based on clustering algorithm
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 8135-8159
Natural Products from Chinese Medicine Targeting NF-κB Signaling: Emerging Therapeutic Avenues for Neurodegenerative Diseases
This review summarizes recent advances in leveraging natural products from Chinese medicine to modulate the nuclear factor kappa B (NF-κB) signaling pathway for the prevention and treatment of neurodegenerative diseases (NDDs), focusing specifically on Alzheimer’s disease (AD), Parkinson’s disease (PD), and Amyotrophic lateral sclerosis (ALS). NF-κB proteins regulate cellular biological activity by binding to promoter regions in the nucleus and transcribing various protein-coding genes. Emerging evidence indicates that NF-κB plays a pivotal role in driving key hallmarks of NDD progression, including neuroinflammation, oxidative stress, mitochondrial dysfunction, and dysregulation of the cell cycle. Natural products from Chinese medicine exert modulatory effects on NF-κB signaling through diverse pharmacological mechanisms, ultimately improving cognitive and motor impairments in preclinical NDDs models. The pleiotropic nature of natural products derived from traditional Chinese medicine (TCM)—which operate through subunit-specific modulation of NF-κB—underscores their potential as next-generation therapeutics. Investigating the intricate regulation of NF-κB by natural products from Chinese medicine will not only enrich our understanding of the pathogenesis of NDDs but also establish a theoretical foundation for the development of new therapeutic drugs for NDDs, providing innovative strategies for prevention and treatment.
- 1 September 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 8135-8159
Open AccessNatural Products from Chinese Medicine Targeting NF-κB Signaling: Emerging Therapeutic Avenues for Neurodegenerative Diseases
This review summarizes recent advances in leveraging natural products from Chinese medicine to modulate the nuclear factor kappa B (NF-κB) signaling pathway for the prevention and treatment of neurodegenerative diseases (NDDs), focusing specifically on Alzheimer’s disease (AD), Parkinson’s disease (PD), and Amyotrophic lateral sclerosis (ALS). NF-κB proteins regulate cellular biological activity by binding to promoter regions in the nucleus and transcribing various protein-coding genes. Emerging evidence indicates that NF-κB plays a pivotal role in driving key hallmarks of NDD progression, including neuroinflammation, oxidative stress, mitochondrial dysfunction, and dysregulation of the cell cycle. Natural products from Chinese medicine exert modulatory effects on NF-κB signaling through diverse pharmacological mechanisms, ultimately improving cognitive and motor impairments in preclinical NDDs models. The pleiotropic nature of natural products derived from traditional Chinese medicine (TCM)—which operate through subunit-specific modulation of NF-κB—underscores their potential as next-generation therapeutics. Investigating the intricate regulation of NF-κB by natural products from Chinese medicine will not only enrich our understanding of the pathogenesis of NDDs but also establish a theoretical foundation for the development of new therapeutic drugs for NDDs, providing innovative strategies for prevention and treatment.
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 7681-7705
Traditional Chinese Medicine Natural Products Targeting Shared Mechanisms of T2DM and AD: Potential Therapeutic Insights
As highly prevalent chronic diseases globally, AD (Alzheimer’s disease) and T2DM (type 2 diabetes mellitus) not only severely affect the quality of life of patients but also impose a significant burden on their families. Numerous studies have gradually revealed that T2DM and AD are bidirectional risk factors, each capable of exacerbating the other. There is a notable correlation in their pathological mechanisms, primarily manifested in insulin resistance, OS (oxidative stress), and inflammatory responses. Currently, available drugs can only delay the progression of AD, such as Donepezil, Galantamine, and Carbamylcholine, making complete cures challenging to achieve. TCM (Traditional Chinese medicine) natural products exhibit characteristics such as multi-targeting, multi-pathway interactions, diverse biological activities, and relatively mild side effects, enabling synergistic intervention in both diseases. In recent years, TCM natural products have garnered increasing attention in research concentrated on the prevention and management of AD and T2DM. This article aims to comprehensively elucidate the collective pathogenic mechanism of AD and T2DM, and explore the progress of TCM natural products based on these mechanisms in the prevention and treatment of both diseases, thereby providing a theoretical foundation for the advancement of innovative treatment tactics.
- 1 September 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 7681-7705
Open AccessTraditional Chinese Medicine Natural Products Targeting Shared Mechanisms of T2DM and AD: Potential Therapeutic Insights
As highly prevalent chronic diseases globally, AD (Alzheimer’s disease) and T2DM (type 2 diabetes mellitus) not only severely affect the quality of life of patients but also impose a significant burden on their families. Numerous studies have gradually revealed that T2DM and AD are bidirectional risk factors, each capable of exacerbating the other. There is a notable correlation in their pathological mechanisms, primarily manifested in insulin resistance, OS (oxidative stress), and inflammatory responses. Currently, available drugs can only delay the progression of AD, such as Donepezil, Galantamine, and Carbamylcholine, making complete cures challenging to achieve. TCM (Traditional Chinese medicine) natural products exhibit characteristics such as multi-targeting, multi-pathway interactions, diverse biological activities, and relatively mild side effects, enabling synergistic intervention in both diseases. In recent years, TCM natural products have garnered increasing attention in research concentrated on the prevention and management of AD and T2DM. This article aims to comprehensively elucidate the collective pathogenic mechanism of AD and T2DM, and explore the progress of TCM natural products based on these mechanisms in the prevention and treatment of both diseases, thereby providing a theoretical foundation for the advancement of innovative treatment tactics.
- 17 June 2025
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 77 (9) , 1203-1221
Naochuxue formula attenuates early brain injury following subarachnoid hemorrhage by inhibiting neuronal apoptosis via network pharmacology and in vivo experiments
Objectives: Investigate Naochuxue formula’s mechanism in the treatment of subarachnoid hemorrhage. Methods: Analyzed Naochuxue formula’s active components via nontargeted metabolomics, and predicted the core targets using network pharmacology. Sprague‒Dawley rats were randomly divided into six groups: sham, model, Naochuxue formula low, medium and high dose groups, and edaravone. Neurological deficits were assessed using the modified Garcia score and tissue damage was assessed by measuring the brain water content. Blood‒brain barrier permeability was assessed using the Evans blue procedure and pathological changes in the lesion site were observed through HE staining and Nissl staining. TUNEL staining and Caspase-3 immunofluorescence were used to observe the apoptosis of neurons in the hippocampus. The distribution and expression of p-PI3K and p-AKT were determined using immunohistochemistry. The expression of the apoptosis-related genes Caspase-3, Bcl-2, and Bax was determined using RT‒PCR. Key findings: Compared with the model group, rats in the high-dose Naochuxue formula group exhibited significant improvements in neurological defects, brain histopathology, blood‒brain barrier permeability and brain edema on Day 3 posttreatment, downregulated Bax and Caspase-3 expression, and significantly upregulated p-PI3K, p-AKT, and Bcl-2 expression (all P < 0.05). Conclusions: High-dose formula for 3 days activated PI3K/AKT signaling pathway, inhibitd neuronal apoptosis, and exerted neuroprotective effects.
- 17 June 2025
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 77 (9) , 1203-1221
Naochuxue formula attenuates early brain injury following subarachnoid hemorrhage by inhibiting neuronal apoptosis via network pharmacology and in vivo experiments
Objectives: Investigate Naochuxue formula’s mechanism in the treatment of subarachnoid hemorrhage. Methods: Analyzed Naochuxue formula’s active components via nontargeted metabolomics, and predicted the core targets using network pharmacology. Sprague‒Dawley rats were randomly divided into six groups: sham, model, Naochuxue formula low, medium and high dose groups, and edaravone. Neurological deficits were assessed using the modified Garcia score and tissue damage was assessed by measuring the brain water content. Blood‒brain barrier permeability was assessed using the Evans blue procedure and pathological changes in the lesion site were observed through HE staining and Nissl staining. TUNEL staining and Caspase-3 immunofluorescence were used to observe the apoptosis of neurons in the hippocampus. The distribution and expression of p-PI3K and p-AKT were determined using immunohistochemistry. The expression of the apoptosis-related genes Caspase-3, Bcl-2, and Bax was determined using RT‒PCR. Key findings: Compared with the model group, rats in the high-dose Naochuxue formula group exhibited significant improvements in neurological defects, brain histopathology, blood‒brain barrier permeability and brain edema on Day 3 posttreatment, downregulated Bax and Caspase-3 expression, and significantly upregulated p-PI3K, p-AKT, and Bcl-2 expression (all P < 0.05). Conclusions: High-dose formula for 3 days activated PI3K/AKT signaling pathway, inhibitd neuronal apoptosis, and exerted neuroprotective effects.
- Open Access
- 1 January 2025
- Published by Aging and Disease in Aging and disease
Mechanisms and Pathogenesis of Diabetic Cognitive Impairment: A Comprehensive Review
Diabetic cognitive impairment (DCI) is a form of cognitive dysfunction that affects individuals with diabetes, marking it as one of the complications linked to this disease. This condition typically presents as deficits in various cognitive abilities, such as memory, learning, language, motor skills, perception, and attention. Studies show that around 13% of diabetic individuals aged 65 to 74 experience cognitive impairment, with this figure rising to 24% for those over 75. As the global incidence of DCI increases, the economic and caregiving challenges for both individuals and society are also growing. The specific mechanisms underlying DCI remain unclear, and the relationships among various pathological processes are still under investigation. The study of DCI mechanisms continues to present numerous unresolved mysteries, such as unclear causal relationships: does metabolic disorder (e.g., hyperglycemia) directly damage neurons, or does it indirectly affect cognition through vascular lesions? Additionally, the mechanisms of individual heterogeneity pose further questions: why do some diabetic patients experience cognitive decline (CD) while others do not? Therefore, understanding the pathological alterations and the fundamental reason behind DCI is essential for improving early prevention and treatment strategies for individuals exhibiting clinical symptoms of this disorder. Furthermore, DCI represents a significant intersection between metabolic and neurodegenerative diseases, which encourages the integration of cognitive assessments into routine diabetes management. This article not only provides a systematic review of existing research but also serves as a bridge connecting basic science with clinical practice, offering theoretical support for the precise prevention and early diagnosis of DCI in patients.
- 1 January 2025
- Published by Aging and Disease in Aging and disease
Open AccessMechanisms and Pathogenesis of Diabetic Cognitive Impairment: A Comprehensive Review
Diabetic cognitive impairment (DCI) is a form of cognitive dysfunction that affects individuals with diabetes, marking it as one of the complications linked to this disease. This condition typically presents as deficits in various cognitive abilities, such as memory, learning, language, motor skills, perception, and attention. Studies show that around 13% of diabetic individuals aged 65 to 74 experience cognitive impairment, with this figure rising to 24% for those over 75. As the global incidence of DCI increases, the economic and caregiving challenges for both individuals and society are also growing. The specific mechanisms underlying DCI remain unclear, and the relationships among various pathological processes are still under investigation. The study of DCI mechanisms continues to present numerous unresolved mysteries, such as unclear causal relationships: does metabolic disorder (e.g., hyperglycemia) directly damage neurons, or does it indirectly affect cognition through vascular lesions? Additionally, the mechanisms of individual heterogeneity pose further questions: why do some diabetic patients experience cognitive decline (CD) while others do not? Therefore, understanding the pathological alterations and the fundamental reason behind DCI is essential for improving early prevention and treatment strategies for individuals exhibiting clinical symptoms of this disorder. Furthermore, DCI represents a significant intersection between metabolic and neurodegenerative diseases, which encourages the integration of cognitive assessments into routine diabetes management. This article not only provides a systematic review of existing research but also serves as a bridge connecting basic science with clinical practice, offering theoretical support for the precise prevention and early diagnosis of DCI in patients.